Showing results (31-40 of 109) with videos related to
Sort By:
Pageof 11
British Journal of Cancer|September 1, 1994
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEAC Haglund, J Lundin, P Kuusela, et al.International Journal of Cancer|April 15, 1987
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9C Haglund, P Kuusela, H Jalanko, et al.International Journal of Cancer|December 15, 1986
Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9C Haglund, J Lindgren, P J Roberts, et al.The American Journal of Surgical Pathology|September 1, 1984
Expression of laminin in pancreatic neoplasms and in chronic pancreatitisC Haglund, P J Roberts, S Nordling, et al.British Journal of Cancer|March 1, 1991
Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinomaC Haglund, J Lindgren, P J Roberts, et al.British Journal of Cancer|June 1, 1987
Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseasesP Kuusela, C Haglund, P J Roberts, et al.Journal of Clinical Pathology|February 10, 2006
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancerA Juuti, J Louhimo, S Nordling, et al.The Journal of Clinical Endocrinology and Metabolism|November 10, 2001
Increased expression of cyclooxygenase-2 in malignant pheochromocytomasK Salmenkivi, C Haglund, A Ristimäki, et al.Histopathology|June 26, 2003
Lack of histologically suspicious features, proliferative activity, and p53 expression suggests benign diagnosis in phaeochromocytomasK Salmenkivi, P Heikkilä, C Haglund, et al.Langenbeck'S Archives of Surgery|January 21, 2021
Impact of pasireotide on postoperative pancreatic fistulas following distal resectionsTiina Vuorela, H Mustonen, A Kokkola, et al.Pageof 11